Attorney Docket No.: 47675-238

First Named Inventor: Isabel D.C. Markl

Filing Date: 27 October 2000

Date of telephonic interview: 10 September 2009

Date of Further Supplemental Response and Amendment: 10 September 2009

Examiner: Jeanine Anne Goldberg

IN THE CLAIMS:

Applicants, pursuant to 37 C.F.R. § 1.121, submit the following amendments to the claims:

- 1. (Currently amended) A method for detecting [[a]] breast cancer, comprising:
- (a) obtaining a tissue sample from a test tissue;
- (b) performing a methylation assay on DNA from the tissue sample, wherein the methylation assay determines a methylation state of a plurality of CpG dinucleotides within CpG dinucleotide methylation state SEQ ID NO:36; and
- (c) comparing the CpG dinucleotide methylation state of the plurality of CpG dinucleotides within SEQ ID NO:36 in the test sample to that of a control DNA state, wherein hypermethylation of the test sample is indicative of breast cancer.
 - 2.-3. (Cancelled)
- 4. (Previously presented) The diagnostic assay of claim 1 wherein the methylation assay procedure is selected from the group consisting of MethyLight, MS-SNuPE, MSP, MCA, COBRA, and combinations thereof.
 - 5.-6. (Cancelled)
- 7. (Previously presented) A kit useful for the detection of a methylated CpG-containing nucleic acid comprising a carrier means containing one or more containers comprising:
- (a) a container containing a probe or primer consisting of at least 12 contiguous nucleotides of a sequence selected from the group consisting of SEQ ID NOS:36 and 37, and the bisulfite-converted sequences thereof; and
- (b) additional standard methylation assay reagents, wherein the kit, based at least in part on the probe or primer, is suitable to determine the methylation status of one or more CpG dinucleotides within the sequence selected from the group consisting of SEQ ID NOS:36 and 37.
- 8. (Previously presented) The kit of claim 7, wherein the additional standard methylation assay reagents are standard reagents for performing a methylation assay from the group consisting of MethyLight, MS-SNuPE, MSP, MCA, COBRA, and combinations thereof.
 - 9. (Cancelled)
 - 10. (Previously presented) An isolated nucleic acid molecule consisting of a

Attorney Docket No.: 47675-238

First Named Inventor: Isabel D.C. Markl

Filing Date: 27 October 2000

Date of telephonic interview: 10 September 2009

Date of Further Supplemental Response and Amendment: 10 September 2009

Examiner: Jeanine Anne Goldberg

methylated or unmethylated polynucleotide sequence selected from the group consisting of sequences of SEQ ID NO:37 and the bisulfite-converted sequences thereof.

- 11. (Original) The nucleic acid of claim 10, wherein the nucleic acid is methylated.
- 12. (Original) The nucleic acid of claim 10, wherein the nucleic acid is unmethylated.
- 13. (Currently amended) A method for detecting [[a]] prostate, breast or colon cancer eancer, comprising:
 - (a) obtaining a tissue sample from a test tissue;
- (b) performing a methylation assay on DNA from the tissue sample, wherein the methylation assay determines a methylation state of a plurality of CpG dinucleotides within CpG dinucleotide methylation state of SEQ ID NO:37; and
- (c) comparing the CpG dinucleotide methylation state of the plurality of CpG dinucleotides within SEQ ID NO:37 in the test sample to that of <u>a</u> control DNA <u>state</u>, wherein hypermethylation of the test sample is indicative of prostate, breast or colon cancer.
 - 14. (Cancelled)
- 15. (Previously presented) The diagnostic assay of claim 13, wherein the methylation assay procedure is selected from the group consisting of MethyLight, MS-SNuPE, MSP, MCA, COBRA, and combinations thereof.
 - 16. (Cancelled)
 - 17. (Cancelled)
 - 18. (Cancelled)
 - 19. (Cancelled)